More than a dozen cancer species usher in innovative therapies! Take stock of the anti-...

February 4th is World Cancer Day, and this year's theme is "Caring for Patients and Fighting Cancer Together".
fact, the fight against cancer has been going on for thousands of years.
Fortunately, with the progress of science and medical development, radiation/chemotherapy, small molecule targeted drugs, antibody drugs, cell therapy and other generations of innovative therapies have come out, cancer treatment has been from "no drugs available" to "precision treatment" of the new era.
incomplete statistics, since 2020, more than 30 innovative anti-cancer drugs have been approved for sale in China or approved for new adaptations, bringing new treatment options to cancer patients.
on this special day, this article will share information on some of the innovative anti-cancer drugs approved in China since 2020.
breast cancer has overtaken lung cancer as the world's most common cancer for the first time, according to the World Health Organization's International Agency for Research on Cancer (IARC) for the first time, according to the latest global cancer burden data for 2020.
public information shows that the most common subsype of breast cancer is HR-/HER2-, accounting for 70% of the total number of breast cancer patients, and about 30% of patients diagnosed with HR-/HER2-early breast cancer still have a risk of cancer recurrence.
2020, China's HER2-positive breast cancer patients have welcomed a number of innovative treatments.
Among them, Roche's Enmetrobeumantin is an antibody-coupled drug (ADC), which has been approved for the first ADC drug approved in China for HER2-positive early breast cancer patients who still have invasive lesions after receiving a new complementary treatment based on the eucalypse-based combined quercetone monotherapy.
Eli Lilly and Company's Abesili tablet is a CDK 4/6 inhibitor approved for local late stage or metastasis breast cancer in HR plus, HER2.
In addition, there are North Sea Kangcheng's Malay acid nairatini tablets, Sansheng National Health Pharmaceuticals' Inito monoanti, the former approved for the treatment of HER2-positive early breast cancer patients intensive complementary treatment, the latter approved HER2-positive metastasis breast cancer.
lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), of which NSCLC accounted for 80%-85%.
2020, a number of new anti-cancer drugs have been approved, covering a wide range of small cell lung cancer, T790M mutation-positive NSCLC, ALK-positive NSCLC, non-scale NSCLC, etc., for lung cancer patients to bring new options.
February 2020, China's widespread small cell lung cancer patients ushered in the first immunotherapy.
Roche's PD-L1 monoanti-anti-athalithropoietic combination chemotherapy was approved for first-line treatment of a wide range of small cell lung cancer.
IMpower133 study showed that atiliju single anti-combination chemotherapy significantly extended the overall survival of patients with small cell lung cancer and reduced the risk of death in the study subjects by 30 percent.
, the IMpower133 study was the first major breakthrough in the first-line treatment of broad-stage small cell lung cancer in 30 years, according to an earlier Roche press release.
, NSCLC patients with EGFR-TKI treatment progressing and T790M mutations have new options.
March 2020, Haussen Pharmaceuticals' third-generation EGFR-TKI Amedini was approved by NMPA for the treatment of adult patients with local late stage or metastasis NSCLC who had previously advanced in EGFR-TKI treatment and were positive for the T790M mutation.
clinical study data showed excellent efficacy and safety in amedinib monotherapy: patients with a medium progression-free survival period (mPFS) of 12.3 months, patients with objective remission rate (ORR) of 68.9%, disease control rate (DCR) of 93.4%, and effective control of brain lesions, brain metastasis patients ORR of 61.5%.
ALC-positive NSCLC patients are also expected to have new treatment options.
novartis' ALC inhibitor Seritinib has been approved for first-line treatment in patients with ALC-positive local late stage or metastasis NSCLC.
's ALK inhibitor Nsateni has also been approved for the treatment of patients with local late stage or metastasis NSCLC who have previously progressed after treatment with clostrini, or who are resistant to alkydinib.
addition, Hengrui Pharmaceutical's PD-1 antibody Karelli pearl monoantigen is also approved for first-line treatment of advanced or metastasis non-scale NSCLC.
PD-1 antibody in Baiji Shenzhou was approved for two chemotherapy programs to treat first-line advanced squamous NSCLC.
liver cancer 2020, there has also been significant progress in the treatment of hepatocellular carcinoma (HCC).
of these, two PD-1/PD-L1 inhibitors were approved for the treatment of hepatocellular carcinoma, and one was the Henri Pharmaceutical PD-1 inhibitor Karelli pearl monoanti, which was approved for treatment with sorapinib and/or containing Treatment of patients with advanced hepatocellular carcinoma with chemotherapy in the Osali platinum system; another is Roche's inhibitor Atiliju monoanti, which has been approved in combination with VEGF inhibitor Beva cytocytocinosis for the treatment of non-excisive hepatocellular carcinoma patients who have not been systematically treated in the past.
In addition, Henrui Pharmaceuticals' VEGFR-2 tyrosine kinase inhibitor (TKI) Apatini has been approved as a new adaptation to liver cancer for the treatment of advanced hepatocellular carcinoma that has failed or is insirible after at least first-line systemic treatment.
cancer is one of the most common cancers in China.
March 2020, China welcomed the first gastric cancer immunotherapy, the PD-1 inhibitor Navuliyu single anti-injection from BMS.
it is approved by the NMPA for the treatment of patients with advanced or relapsed stomach or gastroesophageal connected adenocarcinoma who have previously received two or more systemic treatment options.
this approval breaks the deadlock of "backline deficiency" in gastric cancer treatment in China, which is of great significance for restoring confidence in the treatment of advanced stomach cancer.
study showed that Navuliyu monoantigen reduced the risk of death by 38 percent compared to the control group, doubling the one-year survival rate to 27.3 percent.
At the same time, the data of taiwan population in China were consistent with the overall population results, and compared with the control group, Navuliyu monoantitic injection significantly reduced the risk of death by 51%, which brought great clinical value to the treatment of gastric cancer patients in China.
prostate cancer is the world's second most common malignant tumor in men, metastatic desopathic resistance prostate cancer (CRPC) poor prognosmation, five-year survival rate of about 29%.
prostate cancer has also been described as a "silent killer" that is not easily detected at an early stage, with most patients in China already in their late stages of diagnosis and 54 per cent of patients seeing bone metastasis.
2020, several androgen-infested (AR) inhibitors have been approved for market or new adaptations.
For example, Bayer's Darotamine and Astellas' Enzaluamine softgels have been approved in China for the treatment of non-metastatic desopathic resistance prostate cancer (nmCRPC), Janssen's apatamine tablets have been approved in China for the treatment of metastatic endocrine therapy sensitive prostate cancer (mHSPC) adult patients.
In addition, in August 2020, NMPA approved the world's first α-particle radiation radiotherapy drug, chlorpyrine 223Ra, from Bayer, which was approved in China to treat descending resistance prostate cancer patients with symptomatic bone metastasis and no known visceral metastasis.
study showed that the product significantly improved the overall survival and quality of life of patients, while delaying the on-the-rise of the first symptomatic bone event, resulting in multiple benefits for prostate cancer patients.
head and neck squamous cancer head and neck squamous cancer is one of the most common malignant tumors.
the majority of patients have reached the local late stage, after surgery, chemotherapy, there is still a high proportion of patients will have local recurrence and/or distant metastasis.
2020, China's head and neck squamous cancer patients finally ushered in targeted drugs.
In March 2020, Merck KGaA's anti-EGFR antibody, Sitoxysin, was approved by NMPA and combined with platinum and fluorouracil chemotherapy for first-line treatment of recurrence and/or metastatic head and neck squamous cell carcinoma.
According to an earlier press release issued by Merck in Germany, the approval of this new adaptive drug, sitoxidan, has broken the 30-year-old difficulty of platinum chemotherapy in patients with relapsed and/or metastatic head and neck squamous cell carcinoma in China and filled the gap in targeted treatment in the field of head and neck squamous cancer.
addition, MSD Keytruda has been approved for a new adaptation for first-line single-drug therapy in patients with metastatic or non-removable reoccessive head and neck squamous cell carcinoma (HNSCC) in tumor expression PD-L1.
melanoma is a disease caused by mutations in melanin cell genes, and although melanoma accounts for about 1% of all skin cancers, it is the main cause of death in skin cancer patients and is therefore known as the "King of Skin Cancer".
In March 2020, a new treatment was available for melanoma patients, Novarma's Darafini/Tumedini combination therapy, which was approved by NMPA for complementary treatment after complete removal in patients with stage 3 melanoma who were positive for BRAF V600 mutation.
Darafinib is a powerful and selective BRAF kinase activity inhibitor, and quercinib tablets are a reversible, highly selective MUK1 and MEK2 kinase-active variant inhibitors.
the two drugs can inhibit both BRAF and MEK targets to achieve better results than single drugs. More than
key clinical studies around the world have shown that a combined use of dallafinib and qumentinib can help patients with advanced BRAF V600 mutant melanomas achieve higher disease relief and longer progression-free survival compared to targeted monotherapy.
ovarian cancer is one of the most prevalent gynaecological tumors in China.
most ovarian cancer patients inevitably relapse, although they are relieved after initial platinum-containing chemotherapy.
and options for the treatment of platinum-sensitive relapsed ovarian cancer are still very limited.
2020, two PARP inhibitors have been approved to treat ovarian cancer.
is a Nirapali drug approved for maintenance therapy in adult patients with advanced epitheliotic ovarian, fallopian tube cancer, or primary peritoneal cancer after complete or partial remission of first-line platinum-containing chemotherapy.
Another fluoroopapari capsule from Hengrui Pharmaceuticals has been approved for the treatment of patients with platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer who have underwent second-line and above chemotherapy with embryoline BRCA mutation (gBRCAm).
esophageal cancer is a malignant tumor that is more common in China.
June 2020, China's esophageal cancer sector welcomed two innovative drugs, namely, Carelli Pearl Mono-Resistance of Hengrui Pharmaceuticals and Pabli-Pearl Mono-Resistance of MSD.
among them, Pabliju monoantigen was approved for the evaluation of tumor expression PD-L1 (Comprehensive Positive Score (CPS)≥10) through fully validated testing in patients with previously failed first-line systemic treatment, local late stage or metastatic esophageal squamous cell carcinoma (ESCC).
is approved for the treatment of patients with advanced or insulable localized advanced or metastatic esophageal squamous cancer who have previously received first-line chemotherapy.
According to a multi-center Phase 3 clinical study called ESCORT, Carelli-Pearl monoantigen significantly extended the patient's mesoOS (8.3 months vs 6.2 months) and reduced the risk of death by nearly 30 percent, while ORR was higher (20.2 percent vs 6.4 percent) and sustained remission was longer (7.4 months vs 3.4 months).
more importantly, The Karelli Pearl Monoanti can benefit from all populations.
urethra cancer urethra cancer is currently the most common type of bladder cancer, accounting for more than 90% of bladder cancer cases.
for patients with advanced urethra skin cancer in China, the available treatment options are very limited.
In April 2020, china's urethra skin cancer field ushered in an innovative treatment , the anti-PD-1 antibody drug in Baiji Shenzhou, which was approved for the treatment of patients with local late stage or metastatic PD-L1 high expression of urethra cancer who failed to receive platinum-containing chemotherapy, including new assisted or assisted chemotherapy within 12 months.
it is worth mentioning that this is also China's first approved urethra skin cancer adaptation PD-1 monoantigen.
thyroid cancer is a more common endocrine cancer.
thyroid myelin cancer is a pathological type of thyroid cancer, most thyroid cancer originated from thyroid fig cells, including papyroid cancer, silage cancer, undifferentiated cancer and so on.
in recent months, thyroid cancer patients in China have welcomed two innovative treatments.
first is Eisai's lenvatinib, a multi-target tyrosine kinase inhibitor that has been approved in China for the treatment of differentiated thyroid cancer (DTC) patients.
in a worldwide SELECT study of patients with radioactive iodine refrectable differentiated thyroid cancer, lenphatinib significantly increased the rate of progression-free survival (18.3 months vs. 3.6 months) compared to placebo.
2 is Zhengda Tianqing's Anrotini, a new small molecule multi-target tyrosine kinase inhibitor, recently approved for advanced or metastatic thyroid myelin-like cancer.
study showed that atrotinib therapy extended the patient's mid-level PFS by 9.6 months in the treatment of locally advanced or metastatic thyroid myelin-like cancer.
blood cancer in the field of blood cancer, since 2020 also ushered in a number of innovative products.
the mechanisms and types of these drugs include antibody-coupled drugs (ADCs), BTK inhibitors, BCL-2 inhibitors, CD19×CD3 dual-specific antibodies, and so on, which have been approved in China to treat many types of blood cancers.
Takeda (